ABSTRACT The purpose of this study was to determine whether there is accentuated antagonism between sympathetic and vagal effects on ventricular refractory periods (VRPs) in humans. The effects of 0.04 mg/kg of atropine on the right ventricular effective and functional refractory periods were determined in the setting of ,3-adrenergic blockade by propranolol (0. 15 mg/kg loading dose, then 0. 1 mg/min continuous infusion, group 1) and in the setting of /3-adrenergic stimulation by 25 or 50 ng/kg/min isoproterenol (groups 2 and 3, respectively). Groups 4 to 6 served as control groups. In group 4, VRPs were determined on three occasions separated by 10 min each in the absence of drug. VRPs also were determined on two occasions after infusion of propranolol (group 5) or 25 ng/kg/min of isoproterenol (group 6). Groups 1 to 4 consisted of 10 subjects each, and groups 5 and 6 consisted of five subjects each. VRPs were determined with the use of basic drive cycle lengths of 600, 500, 400, and 350 msec. Because of sinus tachycardia, sufficient data for comparison of groups 1 to 3 were available only at drive cycle lengths of 400 and 350 msec. Atropine significantly shortened the VRPs in groups 1 to 3, but the magnitude of atropine's effects in group 3 (5.3% to 5.8% shortening at drive cycle length of 350 msec) was significantly greater than in group 1 (2.6% to 3.0% shortening, p < .05) Data from the control groups demonstrated that there was no effect of time on measurement of VRPs either in the drug-free state or in the presence of propranolol or isoproterenol. The results of this study indicate that cholinergic tone lengthens VRPs in the absence of background sympathetic activity and that this lengthening of VRPs may become accentuated during /-adrenergic stimulation. 
The purpose of this study was to determine whether there is accentuated antagonism between sympathetic and vagal effects on ventricular refractoriness in humans.
Methods
Study design. The effects of cholinergic blockade on ventricular refractoriness were determined in the presence of 13-adrenergic blockade and /3-adrenergic stimulation. There were six study groups of five to 10 subjects each (table 1). The effects of atropine on the right ventricular effective and functional refractory periods were determined after the infusion of a /3-blocking dose of propranolol (group 1), a 25 ng/kg/min infusion of isoproterenol (group 2) , and a 50 ng/kg/min infusion of isoproterenol (group 3) . The two infusion rates of isoproterenol were used to determine whether the effects of cholinergic blockade are accentuated by progressive j3-adrenergic stimulation. Groups 4 to 6 were control groups. In group 4, ventricular refractory periods were determined on three occasions separated by 10 min each in order to evaluate reproducibility and the effect of time on determination of refractoriness. To ascertain whether Isoproterenol, 25 Isoproterenol, 25 ng/kg/min ng/kg/min AInfusion 1 was continued during infusion 2.
the effects ofpropranolol and isoproterenol on ventricular refractory periods were stable over time, ventricular refractory periods were determined on two occasions separated by 5 min either after the infusion of propranolol (group 5) or after 25 ng/kg/min isoproterenol (group 6). Characteristics of subjects. The subjects of this study were 50 patients who underwent a clinically indicated electrophysiology test. Each subject was in sinus rhythm and was not being treated with any medication known to have a-or /3-adrenergic-blocking properties. Exclusion criteria consisted of treatment with an antiarrhythmic drug, angina pectoris, a systolic blood pressure greater than 160 mm Hg, or diastolic blood pressure greater than 95 mm Hg, atrial fibrillation, and a history of myocardial infarction or cardiac surgery within 3 months of the study. In addition, patients with congestive heart failure were excluded from groups 1 and 5, in which intravenous propranolol was administered.
The clinical characteristics of the subjects are listed in table 2. The subjects in the six study groups did not differ in mean age or left ventricular ejection fraction. Three to eight subjects in each study group (total of 32 subjects) were not being treated with any cardiac medications at the time of the study. Nine patients were being treated with digoxin, eight patients with a diuretic, six patients with captopril, and six patients with a calcium-blocking agent. Subjects in groups 2 and 3 received a continuous infusion of 25 or 50 ng/kg/min of isoproterenol, respectively. These infusion rates were used because they were demonstrated to result in sinus tachycardia in the range of 120 to 150 beats/min in a pilot study. In keeping with the short half-life of isoproterenol and results of a prior study,8 the maximum sinus rate was found to occur by the eighth minute of the infusion. Therefore, to ensure that a steady-state effect was present during testing, measurement of the sinus cycle length, mean arterial pressure, and ventricular refractory periods was delayed for 14 min after the start of the isoproterenol infusion.
Infusion of atropine. The subjects in group 1, 2, and 3 then received 0.04 mg/kg of atropine at a rate of 2 mg/min. This dose of atropine previously was demonstrated to result in block of cholinergic effects on the sinus rate. 6 Two minutes after infusion of atropine, the sinus cycle length, mean arterial pressure, and ventricular refractory periods were measured. The infusion of either propranolol or isoproterenol was continued during this phase of the study.
Plasma propranolol concentrations. In group 1, the plasma propranolol concentration was determined after the measurements were completed after propranolol and again after atropine to ascertain that the plasma propranolol concentration was stable and remained in the range associated with fl-adrenergic blockade. The plasma propranolol concentration was measured by high-performance liquid chromatography with fluorescence detection.9 With this assay, the range of plasma concentrations associated with ,B-adrenergic blockade is 50 to 100 ng/ml. Among the 10 subjects in group 1, the mean plasma propranolol concentration was 73 + 15 ng/ml ( SD) after propranolol and 67 ± 15 ng/ml after atropine.
Control groups. The subjects in group 4 did not receive any drug infusions. The sinus cycle length, mean arterial pressure, and ventricular refractory periods were determined on three occasions separated by 10 min each.
The subjects in group 5 received an intravenous infusion of propranolol in the same manner as in group 1. The sinus cycle length, mean arterial pressure, and ventricular refractory periods were determined on two occasions separated by 5 min.
Isoproterenol was infused at a rate of 25 ng/kg/min in group 6. The sinus cycle length, mean arterial pressure, and ventricular refractory periods were determined 14 min after the start of the infusion and again 5 min later.
Analysis of data. The extent of group differences, differences between measurements obtained in the baseline state and after drug infusions, and interactions between groups and repeated measures were analyzed with a repeated-measures analysis of variance.10
Because of the sinus tachycardia that occurred in response to isoproterenol and atropine, the ventricular refractory periods could not be determined at a basic drive cycle length of 600 msec in groups 2, 3, and 6, and could be determined only in some subjects at basic drive cycle lengths of 500 and 400 msec. When there were missing data, a mixed-model analysis of variance was used to analyze the data. ' 
Results
Effects of propranolol and atropine (group 1). The mean loading dose of propranolol administered in group 1 was 1 1 .8 + 1.9 mg, and the mean dose of atropine was 3.1 ± 0.6 mg.
The effects of propranolol and atropine plus propranol are described in table 3. Propranolol lengthened the sinus cycle length and had no effect on the mean arterial pressure. The ventricular effective refractory periods determined at basic drive cycle lengths of 600, 400, and 350 msec were significantly lengthened by propanolol, but the functional refractory periods were not. ANumbers in parentheses refer to sample size, which was 10 unless otherwise noted; sample size less than 10 occurred because the sinus cycle length was shorter than the basic drive cycle length in some patients.
BNot determined, because the sinus cycle length in each subject was shorter than 500 msec.
Atropine during continued infusion of propanolol significantly shortened the sinus cycle length and had no effect on the mean arterial pressure. The ventricular effective refractory periods determined at basic drive cycle lengths of 500, 400, and 350 ms and the functional refractory periods determined at basic drive cycle lengths of 400 and 350 ms were shortened significantly by atropine. The effects of isoproterenol and isoproterenol plus atropine are described in table 4. Isoproterenol shortened the sinus cycle length and had no effect on the mean arterial pressure. All the measured ventricular refractory periods were significantly decreased by isoproterenol.
Atropine during continued infusion of isoproterenol further shortened the sinus cycle length and had no effect on the mean arterial pressure. After atropine, the ventricular refractory periods could not be determined at basic drive cycle lengths of 600 or 500 msec. The ventricular refractory periods determined at basic drive cycle lengths of 400 and 350 msec were decreased significantly by atropine.
Effects of 50 ng/kg/min isoproterenol and atropine (group 3). The mean dose of isoproterenol administered in group 3 was 3.8 0.7 yg/min, and the mean dose of atropine was 3.0 0.6 mg. Data from these patients are listed in table 5. Isoproterenol shortened the sinus cycle length and had no effect on the mean arterial pressure. All mea-292 sured refractory periods were decreased by isoproterenol.
Atropine during continuous infusion of isoproterenol further shortened the sinus cycle length and had no effect on the mean arterial pressure. Because of sinus tachycardia, the ventricular refractory periods could not be determined at basic drive cycle lengths of 600 or 500 msec after atropine. The ventricular refractory periods determined at basic drive cycle lengths of 400 and 350 msec were decreased significantly by atropine.
Control groups (groups 4 to 6). The data from group 4 are listed in table 6. There were no significant ASample size was three, because the sinus cycle length after atropine was shorter than 400 msec in seven of 10 subjects. Effect ofpropranolol on ventricular refractory periods. In several clinical and experimental studies, it was found that propranolol does not have a significant effect on ventricular refractoriness.5' 13-15 However, in one study propranolol did result in significant prolongation of the mean right ventricular effective refractory period in 10 subjects. 16 The results of the present study confirm that propranolol may increase the right ventricular effective refractory period. This indicates that resting sympathetic activity at least at times may exert a tonic effect on the effective refractory period at the right ventricular apex. It is unlikely that propranolol prolonged ventricular refractoriness by a direct membrane effect, because prior studies have demonstrated that direct membrane effects occur only at plasma propranolol concentrations greater than 150 ng/ml, '7, 18 whereas the plasma propranolol concentrations achieved in the present study were always less than 100 ng/ml.
CIRCULATION
Effects of isoproterenol. The shortening of ventricular refractory periods that occurred in this study in response to isoproterenol confirms the findings of previous clinical studies in which /3-adrenergic stimulation with isoproterenol was found to decrease ventricular refractoriness. [19] [20] [21] Although the effects of isoproterenol on ventricular refractory periods tended to be greater in magnitude with the 50 ng/kg/min infusion than with the 25 ng/kg/min infusion, the difference was significant only for the effective refractory period determined at a basic drive cycle length of 400 msec. However 
